Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 06 Aug 2026, 12:50 PM IST · BSE ID: cf1d98c8-7908-431c-946f-bb4c33e10eb6
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first quarter financial results, showing a net loss in both standalone and consolidated statements.
🤖 AI Summary
- Board approved Un-Audited Standalone and Consolidated Financial Results for Q1 FY27 on August 6, 2026.
- Standalone Net Loss for the quarter ended June 30, 2026, was Rs. (1,611.91) Lakhs.
- Consolidated Net Loss for the quarter ended June 30, 2026, was Rs. (12,761.03) Lakhs.
- Standalone Revenue from operations was Rs. 356.58 Lakhs; Consolidated Revenue was Rs. 356.58 Lakhs.
- R&D Expenses stood at Rs. 1,275.60 Lakhs Standalone and Rs. 12,383.10 Lakhs Consolidated.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations Q1 FY27
356.58 Rs. In Lakhs
91.02
Standalone Net Profit/ (Loss) Q1 FY27
(1,611.91) Rs. In Lakhs
-9.07
Consolidated Revenue from operations Q1 FY27
356.58 Rs. In Lakhs
91.02
Consolidated Net Profit/ (Loss) Q1 FY27
(12,761.03) Rs. In Lakhs
-147.71
Standalone R&D Expenses Q1 FY27
1,275.60 Rs. In Lakhs
145.92
Consolidated R&D Expenses Q1 FY27
12,383.10 Rs. In Lakhs
198.59
🏢 How This Affects the Company
The company operates solely in Research & Development, with significant R&D expenses incurred during the quarter.
The company reported net losses in both standalone and consolidated financials for the quarter, continuing a trend from the previous fiscal year. Finance costs increased to Rs. 47.61 Lakhs (Standalone and Consolidated) from Rs. 15.78 Lakhs in the prior quarter.
Continued significant net losses, combined with high R&D expenditures, indicate ongoing investment in development without immediate offsetting revenue streams. The company has a balance of Rs. 44,813.73 Lakhs from a preferential issue for future utilization.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the reported net losses, which impact earnings per share (Basic EPS Standalone: (0.61) and Consolidated: (4.84) for the quarter ended June 30, 2026).
🔍
Management Signal
The management's continued high R&D spending indicates a focus on long-term product development, despite current period losses.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor net loss trend and R&D expenditure changes.
Updates on utilization of preferential issue proceeds of Rs. 44,813.73 Lakhs.
Allotment of pending 1,85,70,133 warrants and their conversion into equity shares.
HIGH RISK
Substantial and increasing net losses in both standalone and consolidated financials, coupled with high R&D costs, present financial risk.
💡 Investor Takeaway
Suven Life Sciences reported a Standalone Net Loss of Rs. (1,611.91) Lakhs and a Consolidated Net Loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026. This represents a substantial increase in losses compared to the previous year, alongside significant R&D expenditure.
⚖️ Strengths & Concerns
✅ Positives
- Significant Other Income of Rs. 752.36 Lakhs (Standalone and Consolidated) for the quarter ended June 30, 2026.
- A balance amount of Rs. 44,813.73 Lakhs from a preferential issue is available for utilization as of June 30, 2026.
⚠️ Concerns
- Standalone Net Loss increased to Rs. (1,611.91) Lakhs for Q1 FY27 from Rs. (1,477.87) Lakhs in Q1 FY26.
- Consolidated Net Loss substantially increased to Rs. (12,761.03) Lakhs for Q1 FY27 from Rs. (5,151.69) Lakhs in Q1 FY26.
📅 Company Track Record
Suven Life Sciences had previously informed BSE on July 30, 2026, about the Board Meeting scheduled for August 6, 2026, to approve the Q1 FY27 un-audited financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Suven Life Sciences' standalone net profit/loss for Q1 FY27?
Suven Life Sciences reported a standalone Net Loss of Rs. (1,611.91) Lakhs for the quarter ended June 30, 2026, compared to a net loss of Rs. (1,477.87) Lakhs in the prior comparable period.
What was Suven Life Sciences' consolidated net profit/loss for Q1 FY27?
The consolidated Net Loss for Suven Life Sciences for the quarter ended June 30, 2026, was Rs. (12,761.03) Lakhs, significantly higher than the Rs. (5,151.69) Lakhs net loss in Q1 FY26.
What were the R&D Expenses for Suven Life Sciences in Q1 FY27?
Standalone R&D Expenses were Rs. 1,275.60 Lakhs, and Consolidated R&D Expenses were Rs. 12,383.10 Lakhs for the quarter ended June 30, 2026.
How much fund from preferential issue is unutilized by Suven Life Sciences?
As of June 30, 2026, Suven Life Sciences has a balance unutilized amount of Rs. 44,813.73 Lakhs from its preferential issue.
What was Suven Life Sciences' Revenue from operations for Q1 FY27?
Both Standalone and Consolidated Revenue from operations for Suven Life Sciences were Rs. 356.58 Lakhs for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.